Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Subscribe To Our Newsletter & Stay Updated
